Home › NDC Lookup › Ingredients › Ultramicrosize Griseofulvin Tablets › 00115-1724-01
⚪image loading
(from DailyMed)

Ultramicrosize Griseofulvin 125 mg Tablet, Coated, 100-count — NDC 0115-1724-01 (Billing 00115-1724-01)

by Amneal Pharmaceuticals of New York LLC · 100 TABLET, COATED in 1 BOTTLE, PLASTIC

This is a package of 100 tablets of Ultramicrosize Griseofulvin 125 mg Tablet, Coated from Amneal Pharmaceuticals of New York LLC, marketed since Sep 2014 and currently FDA-listed; retail pharmacies pay about $2.65 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00115-1724-01
🏷️ FDA NDC (as labeled) 0115-1724-01 billing pads the labeler segment with a zero
This package
Contains100-count Cost per ea$2.65 NADAC Per package$265.18 / 100 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $2.97/unit · Part D plans $3.30/unit — full pricing hub ↓
Main listing for product 0115-1724 · Also comes in: 500 tablets 0115-1724-02
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0115-1724-01 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0115 labeler · 1724 product · 01 package
Package marketed since
Sep 29, 2014
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
100 EA per package
Barcode (UPC-A, from the NDC)
3 0115172401 3
Medicaid fills, this package
70 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0115-1724-01
Product NDC 0115-1724
11-digit billing NDC 00115172401
NCPDP billing unit EA — each (per item)
Application # ANDA204371
SPL Set ID 0fe90733-bebc-42d5-a098-8f53ad6fab67
Established class (EPC) Tubulin Inhibiting Agent
Physiologic effect Decreased Mitosis; Microtubule Inhibition
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2014-09-29
Route ORAL
Dosage form TABLET, COATED
Substance GRISEOFULVIN
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 009520
GCN 42410
HICL code 004127
Ingredient (HICL) Griseofulvin Ultramicrosize
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W3
Therapeutic class — intermediate (HIC2) Antimycotics
HIC3 code W3A
Therapeutic class — specific (HIC3) Antifungal Antibiotics
AHFS code 08:14.92.00
AHFS class Antifungals, Miscellaneous
FDB label name GRISEOFULVIN ULTRA 125 MG TAB
FDB brand name Griseofulvin Ultramicrosize
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 009520
  • GCN: 42410
  • HICL (First Databank): 004127
  • AHFS class code: 08:14.92.00
Why two NDCs? The FDA registers this code as 0115-1724-01 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00115-1724-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name GRISEOFULVIN ULTRA 125 MG TAB Ingredient Griseofulvin Ultramicrosize
📖 What it is MedlinePlus · NLM

Griseofulvin is used to treat skin infections such as jock itch, athlete's foot, and ringworm; and fungal infections of the scalp, fingernails, and toenails. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats fungal infections of the skin, hair and nails, such as ringworm, athlete’s foot, scalp ringworm and nail fungus. It is used when creams alone are not enough. It will not...
  • Take it by mouth exactly as your prescriber directs. A meal with some fat can help your body absorb it. If you take Ultramicrosize Griseofulvin tablets, they can be crushed into ap...
  • It depends on the infection. Skin infections may take a few weeks, while fingernails take at least 4 months and toenails at least 6. Keep going until the fungus is gone, or the inf...
  • Headache, nausea, upset stomach, diarrhea, rash and tiredness are among the more common ones. Call your doctor for a severe rash or blistering, yellow skin or eyes, or numbness and...
📖 Read our full Griseofulvin guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $2.652 $265.18 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $2.97 $297.31 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $3.30 $330.25 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jul 2025 Mar 2026 Jun 2026 Sep 2026 $3.326 $2.652
▼ Down 20% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00115-1724-01 You're viewing this Main listing 100 TABLET, COATED in 1 BOTTLE, PLASTIC $2.65 / ea $265.18 2014-09-29 — Active
00115-1724-02 0115-1724-02 500 TABLET, COATED in 1 BOTTLE, PLASTIC — — 2014-09-29 — Active

You're viewing the smallest of 2 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet, coated in 1 bottle, plastic.
How does this package differ from NDC 00115-1724-02?
Both are Ultramicrosize Griseofulvin 125 mg Tablet, Coated — the drug itself is identical. This page's package is the 100-count one, while NDC 00115-1724-02 is the 500 tablets package.
What NDC number is used to bill for this package of Ultramicrosize Griseofulvin 125 mg Tablet, Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ultramicrosize Griseofulvin 125 mgthis 00115-1724-01 Amneal 100 tablets $2.652 AB Availability likely —
Ultramicrosize Griseofulvin 125 mg 00781-5827-01 Sandoz 100 tablets $2.652 AB Availability likely —
Ultramicrosize Griseofulvin 125 mg 23155-0863-01 Heritage 100 tablets $2.652 AB Availability likely —
Ultramicrosize Griseofulvin 125 mg 42794-0013-08 Sigmapharm 30 tablets $2.652 AB Availability likely —
Ultramicrosize Griseofulvin 125 mg 62135-0494-01 Chartwell 100 tablets $2.652 AB Availability likely —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2014
On the market since
Sep 2014
📍
2026
Currently FDA-listed
12 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Griseofulvin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAmneal Pharmaceuticals of New York LLC
Application holderMOUNTAIN LLC
FDA applicationANDA204371 (ANDA)
Labeler code00115
First marketedSep 2014
Product typeHuman Prescription Drug
Portfolio228 products on file

More NDCs from Amneal Pharmaceuticals of New York LLC labeler code 00115

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
70
Units reimbursed last 4 qtrs
4.9K
Gross reimbursed last 4 qtrs
$14.6K
Avg / prescription
$208.84
Avg / unit
$2.9731
Latest quarter Q1 2026
34Rx
Medicaid pays / ea
$2.9731
gross reimbursed
vs
NADAC / ea
$2.6518
acquisition cost
=
Spread
+$0.3213
+12% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
50% FFS 50% MCO
Fee-for-service · 35 Rx Managed care · 35 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 2,090 units · 10.7 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 648 units · 9.4 per 100k residents IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 646 units · 9.1 per 100k residents TN North Carolina: 1,533 units · 14.1 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
9.114.1
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 North Carolina 14.1 /100k
2 New York 10.7 /100k
3 Indiana 9.4 /100k
4 Tennessee 9.1 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 tablets this page00115-1724-01 70 Rx · $14,619
500 tablets00115-1724-02 No Medicaid data
Drug total (last 4 qtrs): 70 Rx · 4,917 units · $14,619 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
← 00115-1722-01 · Amneal 00115-1725-01 · Amneal →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.